000 02831cam a2200349 a 4500
003 EG-GiCUC
005 20250223031646.0
008 170206s2016 ua h f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.11.07.Ph.D.2016.Na.T
100 0 _aNagla Fathy Elsalawy
245 1 0 _aTRAIL receptor 1 (DR4) polymorphisms C626G and A683C with hepatocellular carcinoma in Egyptian population /
_cNagla Fathy Elsalawy ; Supervised Ahmad Elsayed Eltaweel , Manal Mohammad Kamal , Tamer Mahmoud Baz
246 1 5 _aالعلاقة بين التعدد الجينى فى التريل جين 1(دى ار 4) فى سى 626جى و اى 683 سى مع سرطان الكبد فى المجتمع المصرى
260 _aCairo :
_bNagla Fathy Elsalawy ,
_c2016
300 _a158 P. :
_bfacsimiles ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
520 _aHepatocellular carcinoma is the most common primary tumor of the liver. The molecular determinants of the HCC progression are still under investigations. TRAIL receptor 1 plays a very important role in many types of cancers including HCC. Genetic polymorphisms of TRAIL DR4, can modulate death signal transduction, which is important in induction of apoptosis and cause increase in the tumor progression. The aim of the present study was to investigate the effect of the DR4 polymorphisms C626G (Thr209Arg, rs20575) and A638C (Glu228Ala, rs20576) on the occurrence of hepatocellular carcinoma in Egyptian patients chronically infected with HCV. Genotyping of the candidate genes was performed by real time PCR assay in 80 HCC patients on top of HCV infection, and 80 HCV patients. The frequency distribution of rs20575 genotypes showed a statistically significant difference between the two studied groups (p = 0.020), the carriers of the C allele were 2.01 times more likely to develop HCC than the carriers of the G allele (p = 0.003), while no significant difference in rs20576 genotypes distribution was found between the studied groups (p = 0.680). On combining the carriers of C allele of rs20575 and the carriers of A allele of rs20576, a significant difference was detected (p > 0.001) with 2,85 higher risk of HCC development in patients who carried both genetic risk alleles simultaneously
530 _aIssued also as CD
653 4 _aC626G and A683C
653 4 _aHepatocellular carcinoma
653 4 _aTRAIL 1 DR4
700 0 _aAhmad Elsayed Eltaweel ,
_eSupervisor
700 0 _aManal Mohammad Kamal ,
_eSupervisor
700 0 _aTamer Mahmoud Baz ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aSamia
_eCataloger
942 _2ddc
_cTH
999 _c59696
_d59696